

FOR RELEASE
9 November 2006

Contact: Laura Strong, Ph.D.
(608) 441-2950
LauraS@quintbio.com

Quintessence Biosciences Confirms Selection of EVade™ Ribonuclease Cancer Treatment for Late Stage Pre-clinical Studies

Madison, WI – Quintessence Biosciences, Inc. today confirmed the selection of a compound from its proprietary EVade™ Ribonuclease program for advancement to preclinical testing and human clinical trials. Results for QBI-139 were presented at the joint meeting of the European Organization for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute, (NCI), and the American Association for Cancer Research (AACR) meeting in Prague (Abstract Number 408).

QBI-139 is an EVade™ Ribonuclease, a class of analogs of the human pancreatic Ribonuclease 1. In preclinical disease models, QBI-139 showed an exceptional safety profile and outstanding tumor growth inhibition *in vivo* against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. Over 30 different EVade™ Ribonucleases have been tested to date and QBI-139 had the best therapeutic index as well as the broadest efficacy in multiple tumor lines.

Pending a favorable preclinical safety assessment, Quintessence estimates submission of an Investigational New Drug application (IND) for this compound in late 2007. Subject to U.S. Food and Drug Administration (FDA) review, the submission of an IND would allow the Company to initiate a Phase I human clinical trial, expected to start in early 2008.

“QBI-139 is the first of some very exciting compounds identified in our drug development efforts,” said Quintessence Biosciences President and CEO Ralph Kauten. “Because of the similarity between the native human protein and EVade™ Ribonucleases, we have great expectations that our candidates will lead to a new class of cancer therapies that are well tolerated by patients.”

EVade™ Ribonucleases can also be used as cytotoxic payloads in targeted therapies, such as monoclonal antibodies. Quintessence is engaged in partnerships for the development of these targeted ribonucleases.

Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of cancer therapies. The Company’s vision is to improve the lives of cancer patients by developing new drugs based on our proprietary EVade™ Ribonuclease technologies. For more information, visit www.quintbio.com.